Drug intelligence / Profile preview

JMN3-003

Development stage: Preclinical
Lead developer: Drug Innovations at Emory
Modality: Small Molecules

Overview

JMN3-003 (also known as compound 6p) is a preclinical, host-directed small molecule antiviral developed by Drug Innovation Ventures at Emory (DRIVE). It is a benzimidazole-based compound designed to treat myxovirus infections, including influenza (orthomyxoviruses) and various paramyxoviruses. The drug's mechanism of action involves modulating host cell factors that are essential for the activity of the viral RNA-dependent RNA polymerase (RdRp) complex. By targeting host-side requirements for viral replication rather than the virus itself, JMN3-003 aims to provide a broad-spectrum therapeutic effect with a high genetic barrier to the development of viral resistance. Preclinical data indicates low nanomolar potency (EC50 ~30-40 nM) against various viral strains, and ongoing research focuses on optimizing the compound's potency and aqueous solubility.

Other names: Unnamed Myxovirus inhibitors

Beyond the preview

Go deeper on JMN3-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMN3-003.

Explore the full profile